BCR-ABL Mutation Detection Kit

The AmoyDx BCR-ABL Mutation Detection Kit is a sensitive and selective assay for the detection of the T315I mutation in the BCR-ABL gene. The majority (95%) of patients with chronic myelogenous leukemia (CML) have a chromosomal rearrangement that produces the BCR-ABL1 fusion oncogene. Patients with CML typically respond very well to treatment with the tyrosine kinase inhibitor imatinib mesylate [1], known as Gleevec in the US and Glivec in Europe. However, CML cells in patients treated with TKIs may develop resistance to the drug due to the appearance of the T315I point mutation in the BCR-ABL kinase domain [2]. New inhibitors such as dasatinib and nilotinib are significantly more potent than imatinib and may overcome resistance.